Albert J. Robichaud Ph.D.
Net Worth
Last updated:
What is Albert J. Robichaud Ph.D. net worth?
The estimated net worth of Dr. Albert J. Robichaud Ph.D. is at least $8,413,746 as of 9 Dec 2019. He owns shares worth $1,185,316 as insider and has received compensation worth at least $7,228,430 in Sage Therapeutics, Inc..
What is the salary of Albert J. Robichaud Ph.D.?
Dr. Albert J. Robichaud Ph.D. salary is $657,130 per year as Chief Scientific Officer in Sage Therapeutics, Inc..
How old is Albert J. Robichaud Ph.D.?
Dr. Albert J. Robichaud Ph.D. is 64 years old, born in 1961.
What stocks does Albert J. Robichaud Ph.D. currently own?
As insider, Dr. Albert J. Robichaud Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Sage Therapeutics, Inc. (SAGE) | Chief Scientific Officer | 136,400 | $8.69 | $1,185,316 |
What does Sage Therapeutics, Inc. do?
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Albert J. Robichaud Ph.D. insider trading
Sage Therapeutics, Inc.
Dr. Albert J. Robichaud Ph.D. has made 6 insider trades between 2014-2019, according to the Form 4 filled with the SEC. Most recently he purchased 25,000 units of SAGE stock on 9 Dec 2019.
The largest trade he's ever made was exercising 60,000 units of SAGE stock on 14 Dec 2017. As of 9 Dec 2019 he still owns at least 136,400 units of SAGE stock.
Sage Therapeutics key executives
Sage Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Albert J. Robichaud Ph.D. (64) Chief Scientific Officer
- Dr. Jeffrey M. Jonas (72) Chief Innovation Officer, Chair of the Science & Technology Forum and Director
- Mr. Barry E. Greene (62) Pres, Chief Executive Officer & Director
- Ms. Anne Marie Cook (63) Senior Vice President, Gen. Counsel & Sec.
- Ms. Kimi E. Iguchi (63) Chief Financial Officer & Treasurer